CA2304119A1 - Modulation de reactions immunitaires - Google Patents

Modulation de reactions immunitaires Download PDF

Info

Publication number
CA2304119A1
CA2304119A1 CA002304119A CA2304119A CA2304119A1 CA 2304119 A1 CA2304119 A1 CA 2304119A1 CA 002304119 A CA002304119 A CA 002304119A CA 2304119 A CA2304119 A CA 2304119A CA 2304119 A1 CA2304119 A1 CA 2304119A1
Authority
CA
Canada
Prior art keywords
group
immune
animal
alkyl
alkenyl groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002304119A
Other languages
English (en)
Inventor
Derrick Cecil Attfield
Volker Reinhard Schillack
Johannes Beyers Van Den Bogaarden
Carl John Landauer
Gabriel Johannes Du Preez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FRANGOLD HOLDINGS Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2304119A1 publication Critical patent/CA2304119A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé permettant d'influencer ou de moduler chez un animal une stimulation ou une suppression du produit de cellules immunitaires, suite à une réaction immunitaire à un stimulant immunitaire externe ou endogène. Le procédé comporte les étapes consistant à administrer à cet animal une quantité efficace du point de vue d'une modulation immunitaire, et non toxique, d'un composé sélectionné dans le groupe constitué par des composés représentés par la formule (I) chimique générale: R¿1?-CO-NR¿2?R¿3? (I), dans laquelle R¿1? est sélectionné dans le groupe constitué par H, un groupe alkyle inférieur (c.-à-d. C¿1? à C¿3?) et un groupe alcényle C¿2? à C¿3?; R¿2? et R¿3? sont les mêmes ou différents, et chacun est sélectionné dans le groupe constitué par H, un groupe alkyle inférieur (c.-à-d. C¿1? à C¿3?) et un groupe alcényle C¿2? à C¿3? qui peuvent être éventuellement halogénés ou hydroxylés, ou lorsqu'ils sont combinés l'un avec l'autre, peuvent former un groupe -(CH¿2?)¿n? dans lequel n est un nombre compris entre 2 et 5, ou le groupe -(CH¿2?)¿2?-O-(CH¿2?)¿2?, des métabolites ou des promédicaments de ceux-ci. Le procédé est utile pour traiter diverses affections associées à des réactions immunitaires inappropriées. L'invention concerne l'utilisation de composés représentés par la formule (I) pour fabriquer des médicaments utiles pour le traitement de telles affections, et des préparations pharmaceutiques renfermant ceux-ci.
CA002304119A 1997-09-16 1998-09-16 Modulation de reactions immunitaires Abandoned CA2304119A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA978319 1997-09-16
ZA97/8319 1997-09-16
PCT/US1998/019126 WO1999013885A1 (fr) 1997-09-16 1998-09-16 Modulation de reactions immunitaires

Publications (1)

Publication Number Publication Date
CA2304119A1 true CA2304119A1 (fr) 1999-03-25

Family

ID=25586589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002304119A Abandoned CA2304119A1 (fr) 1997-09-16 1998-09-16 Modulation de reactions immunitaires

Country Status (10)

Country Link
EP (1) EP1019063A4 (fr)
JP (1) JP2001516721A (fr)
CN (1) CN1279612A (fr)
AU (1) AU737867B2 (fr)
BR (1) BR9812321A (fr)
CA (1) CA2304119A1 (fr)
IL (1) IL135091A0 (fr)
NO (1) NO20001341L (fr)
NZ (1) NZ503418A (fr)
WO (1) WO1999013885A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2324631A1 (fr) * 2000-10-26 2002-04-26 Virodene Pharmaceutical Holdings (Proprietary) Limited Substance ou composition pour le traitement du cancer
AP2006003648A0 (en) * 2003-12-05 2006-06-30 Namibia Medical Invest Pty Ltd Patch

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814659A (en) * 1996-04-23 1998-09-29 Dtr Dermal Therapy (Barbados) Inc. Topical analgesic composition

Also Published As

Publication number Publication date
WO1999013885A1 (fr) 1999-03-25
IL135091A0 (en) 2001-05-20
NO20001341L (no) 2000-05-16
JP2001516721A (ja) 2001-10-02
AU9389098A (en) 1999-04-05
NZ503418A (en) 2001-02-23
EP1019063A4 (fr) 2003-09-03
NO20001341D0 (no) 2000-03-15
CN1279612A (zh) 2001-01-10
EP1019063A1 (fr) 2000-07-19
AU737867B2 (en) 2001-09-06
BR9812321A (pt) 2000-09-05

Similar Documents

Publication Publication Date Title
Kaufman Clinical cure of herpes simplex keratitis by 5-iodo-2'-deoxyuridine
Birkmayer et al. Implications of combined treatment with'Madopar'and L-deprenil in Parkinson's disease: a long-term study
EP0196415B1 (fr) Trichostatines A et C comme agents anti-tumeurs
ES2240163T3 (es) Utilizaciones terapeuticas de polimeros y de oligomeros a base de gamma-hidroxibutirano (ghb).
Wu et al. Recombinant osteopontin attenuates brain injury after intracerebral hemorrhage in mice
JP2004518653A (ja) 不安障害を治療する方法
Qin et al. Effects of naringin on learning and memory dysfunction induced by gp120 in rats
Palin et al. The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNFα-induced sickness behavior
Olianas et al. Inhibition of TNF-α-induced neuronal apoptosis by antidepressants acting through the lysophosphatidic acid receptor LPA1
Li et al. Interleukin-27 prevents LPS-induced inflammatory osteolysis by inhibiting osteoclast formation and function
Constantin et al. Sulfatides trigger cytokine gene expression and secretion in human monocytes
AU737867B2 (en) Modulation of immune responses
Ren et al. Staphylococcus aureus Protein A induces osteoclastogenesis via the NF‑κB signaling pathway
Nathanson et al. Diffusion of Sulfonamides and Penicillin into Fibrin.
Klein et al. Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice
Chang Mechanism of action of colchicine. II. Effects of colchicine and its analogs on phagocytosis and chemotaxis in vitro.
CN1329497A (zh) 对乙型肝炎病毒的联合治疗
Mondino et al. Complement inhibitors in normal cornea and aqueous humor.
CN105311636B (zh) 一种抗疱疹病毒软膏剂及其制备方法
CN101701218B (zh) 一种抑制Th1和Th17分化的免疫调节性寡聚脱氧核苷酸及应用
Kaiser et al. Delayed recall of active tetanus immunization
ES2281195T3 (es) Factores inmunomoduladores para el tratamiento inmunosupresor y antialergico.
US11944601B2 (en) Applications of ellagic acid in preparation of immunomodulatory medicines for treatment of neuromyelitis optica or immune rejection after skin transplantation
RU2008902C1 (ru) Способ лечения туберкулеза легких с преимущественно экссудативным типом воспаления
DOWLING et al. LIQUID VERSUS SOLID PENICILLIN IN OIL AND WAX: The Effect of Particle Size and Type of Penicillin

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued